Euroscreen S.A.

"We are pleased that the Euroscreen collaboration has reached the compound optimization stage with deliverables that expand our preclinical drug discovery portfolio," said Michael Williams, VP, WW Discovery Research at Cephalon.
"The achievement of this milestone validates our lead optimization strategy and is consistent with Euroscreen's evolution as a drug discovery company.  We are proud to have delivered multiple, patentable, drug-like chemical series to Cephalon" said Jean Combalbert, CEO of Euroscreen.  "We believe these compounds will have the ability to effectively compete with other compounds targeting the same GPCR and will advance drug discovery in the area."

- ends -

About Euroscreen SA

Euroscreen is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs.  Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

Euroscreen pursues a dual business model strategy of combining its internal programs on high value targets (EUROSCREEN DRUG DISCOVERY) with its fully dedicated Business Unit (EUROSCREEN FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

Euroscreen has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Monogram Biosciences, Novartis and Pfizer. (www.euroscreen.com)

For further information, please contact:

Euroscreen SA
Tél: +32 71 348 500
Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Alfred Gray, Ph.D. and Vincent Lannoy, Ph.D.
Euroscreen Business Development